523 related articles for article (PubMed ID: 30224261)
1. Effectiveness of CHA
van Doorn S; Rutten FH; O'Flynn CM; Oudega R; Hoes AW; Moons KGM; Geersing GJ
Int J Cardiol; 2018 Dec; 273():123-129. PubMed ID: 30224261
[TBL] [Abstract][Full Text] [Related]
2. Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany.
Wicke FS; Schaller MA; Karymova K; Beyer M; Müller BS
BMC Cardiovasc Disord; 2019 Apr; 19(1):94. PubMed ID: 31014253
[TBL] [Abstract][Full Text] [Related]
3. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
[TBL] [Abstract][Full Text] [Related]
4. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH
Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920
[TBL] [Abstract][Full Text] [Related]
5. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.
Balaghi-Inalou M; Parsa SA; Gachkar L; Andalib S
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):61-64. PubMed ID: 29076078
[TBL] [Abstract][Full Text] [Related]
7. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
Senoo K; Lane DA; Lip GY
Int J Cardiol; 2015 Feb; 181():247-54. PubMed ID: 25528530
[TBL] [Abstract][Full Text] [Related]
8. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
[TBL] [Abstract][Full Text] [Related]
9. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
10. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
[TBL] [Abstract][Full Text] [Related]
11. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
[TBL] [Abstract][Full Text] [Related]
12. CHA
Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.
Dupree L; DeLosSantos M; Smotherman C
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
Zhu WG; Xiong QM; Hong K
Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
Lip GY; Skjøth F; Rasmussen LH; Larsen TB
J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
[TBL] [Abstract][Full Text] [Related]
17. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
Hsu JC; Huang YT; Lin LY
Aging (Albany NY); 2020 Nov; 12(23):24219-24227. PubMed ID: 33226371
[TBL] [Abstract][Full Text] [Related]
18. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
19. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.
Shantsila E; Wolff A; Lip GY; Lane DA
Br J Gen Pract; 2015 Jan; 65(630):e16-23. PubMed ID: 25548312
[TBL] [Abstract][Full Text] [Related]
20. CHA
Kim TH; Yang PS; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Jun; 48(6):1524-1530. PubMed ID: 28455320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
